Hirokazu Okayama

20PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Photochemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 15, 2026
Longitudinal Changes in Nutritional, Inflammatory, and CT-Derived Body Composition Markers During Adjuvant Chemotherapy for Stage II/III Colorectal Cancer.

|Jun 26, 2026
Prognostic Factors for Cancer-Specific Survival after Recurrence in Chemo-Naïve Stage I-III Colorectal Cancer.

|May 18, 2026
Prognostic Impact of Histologic Subtypes in Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer: A Single-Center Retrospective Study of 1127 Stage 0-IV Patients.

|Jan 10, 2026
Evaluation of NTRK Fusions Detection Method in Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma.

Tomoyuki Momma, Motonobu Saito, Shotaro Nakajima

|Nov 27, 2025
KRAS G12A Identifies a High-Risk Subset in Resected Stage II-III Colorectal Cancer.

Tomoyuki Momma, Hirokazu Okayama, Sohei Hayashishita

|Aug 18, 2025
GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression.

Hiroya Suzuki, Hirokazu Okayama, Shotaro Nakajima

Pageof 4

Frequent Collaborators

13 joint publications

Motonobu Saito

10 joint publications

Kosaku Mimura

8 joint publications

Shotaro Nakajima

4 joint publications

Wataru Sakamoto